摘要：2011年9月23日美国FDA批准Soliris（eculizumab）用于治疗非典型溶血尿毒综合征（aHUS）,aHUS可导致肾衰和慢性血液疾病,还伴有增高死亡和卒中的风险。aHUS占所有溶血性尿毒综合征病例的5%～10%,严重影响儿童健康。
注：因版权方要求，不能公开全文，如需全文，请咨询杂志社
热门期刊服务
Journal of Hydrodynamics Journal of Huazhong University of Science and Technology The Journal of China Universities of Posts and Telecommunications Journal of Genetics and Genomics Journal of Iron and Steel Research Journal of Systems Science and Complexity World Journal of Gastroenterology Journal of Computer Science and Technology Applied Mathematics:A Journal of Chinese Universities International Journal of Minerals Metallurgy and Materials International Journal of Mining Science and Technology Journal of Systems Science and Systems Engineering